You are about to leave this site and are being redirected to another site. Would you like to leave this site?
BAVENCIO® (avelumab) is the FIRST and ONLY approved immunotherapy maintenance treatment for certain patients with advanced urothelial carcinoma
BAVENCIO is a prescription medicine used to treat a type of cancer in the bladder or urinary tract called urothelial carcinoma (UC) when it has spread or cannot be removed by surgery (advanced UC). BAVENCIO may be used as maintenance treatment when your cancer has responded or stabilized after you have received platinum-containing chemotherapy as your first treatment. It is not known if BAVENCIO is safe and effective in children.